BAFFR CAR-T

Phase 1Cell therapy

GGuangzhou Bio-gene Technology Co., Ltd

BAFFR CAR-T is one of 49 biologic programs targeting Relapsed/Refractory. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed/refractoryNot yet recruiting

Relapsed/refractoryPhase 1

Not yet recruiting

Competition

Competitive Landscape

64 competitors in Relapsed/refractory

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

9 2

Rituxan

Roche

Phase 2

9 3

Venclexta

AbbVie

Phase 2

8 4

Fludara

Sanofi

Phase 2

7 5

Keytruda

Merck & Co.

Phase 2

4 6

Opdivo

Bristol-Myers Squibb

Phase 2

4 7

Adcetris

Pfizer

Phase 2

2 8

Gemzar

Johnson & Johnson

Phase 2

2 9

Velban

Eli Lilly

Phase 2

1 10

Eloxatin

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Not yet recruiting

Relapsed/refractory

NCT07196111

Clinical

Trials by Indication[1]

Relapsed/Refractory1 trial

BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors

Not yet recruiting·GGuangzhou Bio-gene Technology Co., Ltd·Phase 1·NCT07196111·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BAFFR CAR-T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BAFFR CAR-T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BAFFR CAR-T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou Bio-gene Technology Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: GGuangzhou Bio-gene Technology Co., Ltd

BAFFR CAR-T

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Relapsed/Refractory1 trial

References

Drug Info

Quick Facts

Related News